Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMK34MZ)

Drug Name
Xilonix Drug Info
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [1]
Influenza virus infection 1E30-1E32 Phase 3 [2]
Non-small-cell lung cancer 2C25.Y Phase 2 [3]
Cross-matching ID
TTD Drug ID
DMK34MZ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-1 alpha (IL1A) TTPM6HI IL1A_HUMAN Modulator [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-1 alpha (IL1A) DTT IL1A 4.626 4.89 5.338 5.448
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Colorectal cancer
ICD Disease Classification 2B91.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-1 alpha (IL1A) DTT IL1A 7.52E-01 1.41E-02 0.09
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02138422) A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Xbiotech.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of xbiotech.